GlassScriptPhysician profile
Sagar Bhula
NPI 1386271906
$919.76
in general payments reported to CMS, 2019-2025
10 companies · $415 in 2025
The $415 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.11 · 2023: $31.69 · 2024: $451 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $449.22 | 2024-2025 | Tezspire, Airsupra, Fasenra |
| Merck Sharp & Dohme LLC | $160.90 | 2024-2025 | Zerbaxa, Recarbrio |
| United Therapeutics Corporation | $114.39 | 2024-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $49.22 | 2024-2025 | Uptravi, Opsumit |
| Genzyme Corporation | $31.69 | 2023 | |
| Pulmonx Corporation | $30.95 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Regeneron Healthcare Solutions, INC. | $26.87 | 2024 | Dupixent |
| Epizyme, INC. | $22.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.46 | 2025 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $16.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Bhula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.